The spice for joint inflammation: Anti-inflammatory role of curcumin in treating osteoarthritis

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 3029-3042

  Chin, Kok Yong ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Cartilage; Chondrocyte; Curcuma; Inflammation; Joint; Pain

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CURCUMA EXTRACT; CURCUMIN; CURCUMINOID DERIVATIVE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; PLACEBO; PLANT EXTRACT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEOGLYCAN; STROMELYSIN; UNCLASSIFIED DRUG; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ADVERSE DRUG REACTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRALGIA; B LYMPHOCYTE; CARTILAGE CELL; CELL NUCLEUS; CLINICAL TRIAL (TOPIC); CURCUMA; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; ENHANCER REGION; ENZYME RELEASE; GENE ACTIVATION; HUMAN; IN VITRO STUDY; JOINT FUNCTION; NONHUMAN; OSTEOARTHRITIS; PHYSICAL ACTIVITY; PROSTAGLANDIN RELEASE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; PROTEOGLYCAN SYNTHESIS; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; CHEMISTRY; CHONDROCYTE; DRUG EFFECTS; METABOLISM; SPICE;

ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHONDROCYTES; CURCUMIN; CYCLOOXYGENASE 2; HUMANS; NF-KAPPA B; OSTEOARTHRITIS; SPICES;

EID: 84989191907     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S117432     Document Type: Review

References (69)

1. Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage. 2015;23(8):1233-1241.
2. Altman R, Asch E, Bloch D, et al. Development of criteria for the classi-fication and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and therapeutic criteria committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039-1049.
3. Centers for Disease Control and Prevention. Osteoarthritis (OA); 2015. Available from: http://www.cdc.gov/arthritis/basics/osteoarthritis.htm. Accessed June 18, 2016.
4. Cross M, Smith E, Hoy D, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-1330.
5. Dillon CF, Rasch EK, Gu Q, Hirsch R. Prevalence of knee osteoarthritis in the United States: arthritis data from the Third National Health and Nutrition Examination Survey 1991-1994. J Rheumatol. 2006;33(11):2271-2279.
6. Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011;342:d1165.
7. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196.
8. Ruiz D Jr, Koenig L, Dall TM, et al. The direct and indirect costs to society of treatment for end-stage knee osteoarthritis. J Bone Joint Surg Am. 2013;95(16):1473-1480.
9. Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis. 2005;64(9):1263-1267.
10. Sohn DH, Sokolove J, Sharpe O, et al. Plasma proteins present in osteoarthritic synovial fluid can stimulate cytokine production via Toll-like receptor 4. Arthritis Res Ther. 2012;14(1):R7.
11. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculosk-elet Dis. 2013;5(2):77-94.
12. Blanco FJ, Rego I, Ruiz-Romero C. The role of mitochondria in osteoarthritis. Nat Rev Rheumatol. 2011;7(3):161-169.
13. Hochberg MC, Altman RD, April KT, et al. American College of Rheu-matology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474.
14. Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A system-atic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum. 2014;43(6):701-712.
15. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
16. Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research pub-lished through January 2009. Osteoarthritis Cartilage. 2010;18(4):476-499.
17. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage. 2007;15(9):981-1000.
18. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22(6):559-570.
19. Skou ST, Roos EM, Laursen MB, et al. A randomized, controlled trial of total knee replacement. N Engl J Med. 2015;373(17):1597-1606.
20. Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv. 2014;32(6):1053-1064.
21. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem. 2008;114(2):127-149.
22. Buhrmann C, Mobasheri A, Busch F, et al. Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2011;286(32):28556-28566.
23. Fu XY, Yang MF, Cao MZ, et al. Strategy to suppress oxidative damage-induced neurotoxicity in PC12 cells by curcumin: the role of ROS-mediated DNA damage and the MAPK and AKT pathways. Mol Neurobiol. 2016;53(1):369-378.
24. Wu J, Li Q, Wang X, et al. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. PLoS One. 2013;8(3):e59843.
25. Cui Q, Li X, Zhu H. Curcumin ameliorates dopaminergic neuronal oxidative damage via activation of the Akt/Nrf2 pathway. Mol Med Rep. 2016;13(2):1381-1388.
26. Ak T, Gulcin I. Antioxidant and radical scavenging properties of cur-cumin. Chem Biol Interact. 2008;174(1):27-37.
27. Panahi Y, Sahebkar A, Parvin S, Saadat A. A randomized controlled trialon the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem. 2012;49(Pt 6):580-588.
28. Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflam-mation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28(10):1461-1467.
29. Singh AK, Vinayak M. Curcumin attenuates CFA induced thermal hype-ralgesia by modulation of antioxidant enzymes and down regulation of TNF-alpha, IL-1beta and IL-6. Neurochem Res. 2015;40(3):463-472.
30. Xu D, Hu L, Su C, et al. Tetrachloro-p-benzoquinone induces hepatic oxidative damage and inflammatory response, but not apoptosis in mouse: the prevention of curcumin. Toxicol Appl Pharmacol. 2014;280(2):305-313.
31. Moon DO, Kim MO, Choi YH, Park YM, Kim GY. Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. Int Immunopharmacol. 2010;10(5):605-610.
32. Badria FA, El-Farahaty T, Shabana AA, Hawas SA, El-Batoty MF. Boswellia-curcumin preparation for treating knee osteoarthritis: a clinical evaluation. Altern Complement Ther. 2002;8(6):341-348.
33. Nakagawa Y, Mukai S, Yamada S, et al. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J Orthop Sci. 2014;19(6):933-939.
34. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of systemic oxidative stress by curcuminoids in osteoarthritis: results of a random-ized controlled trial. J Diet Suppl. 2016;13(2):209-220.
35. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28(11):1625-1631.
36. Rahimnia AR, Panahi Y, Alishiri G, Sharafi M, Sahebkar A. Impact of supplementation with curcuminoids on systemic inflammation in patients with knee osteoarthritis: findings from a randomized double-blind placebo-controlled trial. Drug Res (Stuttg). 2015;65(10):521-525.
37. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014;9:451-458.
38. Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis. J Altern Comple-ment Med. 2009;15(8):891-897.
39. Kizhakkedath R. Clinical evaluation of a formulation containing Cur-cuma longa and Boswellia serrata extracts in the management of knee osteoarthritis. Mol Med Rep. 2013;8(5):1542-1548.
40. Kertia N, Asdie AH, Rochmah W, Marsetyawan. Ability of cur-cuminoid compared to diclofenac sodium in reducing the secretion of cycloxygenase-2 enzyme by synovial fluid’s monocytes of patients with osteoarthritis. Acta Med Indones. 2012;44(2):105-113.
41. Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2010;15(4):337-344.
42. Belcaro G, Cesarone MR, Dugall M, et al. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med. 2010;52(2 Suppl 1):55-62.
43. Belcaro G, Dugall M, Luzzi R, et al. Meriva(R)+Glucosamine versus Chondroitin + Glucosamine in patients with knee osteoarthritis: an obser-vational study. Eur Rev Med Pharmacol Sci. 2014;18(24):3959-3963.
44. Madhu K, Chanda K, Saji MJ. Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology. 2013;21(2):129-136.
45. Appelboom T, Maes N, Albert A. A new curcuma extract (flexofytol(R)) in osteoarthritis: results from a belgian real-life experience. Open Rheumatol J. 2014;8:77-81.
46. Henrotin Y, Gharbi M, Dierckxsens Y, et al. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treat-ment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med. 2014;14:159.
47. Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B. Treat-ment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. 1991;33(1-2):91-95.
48. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853(1-2):183-189.
49. Liu W, Zhai Y, Heng X, et al. Oral bioavailability of curcumin: problems and advancements. J Drug Target. 2016;24(8):694-702.
50. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol. 2007;60(2):171-177.
51. Sunagawa Y, Hirano S, Katanasaka Y, et al. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study. J Nutr Sci Vitaminol (Tokyo). 2015;61(1):37-44.
52. Morimoto T, Sunagawa Y, Katanasaka Y, et al. Drinkable preparation of Theracurmin exhibits high absorption efficiency - a single-dose, double-blind, 4-way crossover study. Biol Pharm Bull. 2013;36(11):1708-1714.
53. Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Thera-curmin) in cancer patients. Cancer Chemother Pharmacol. 2013;71(6):1521-1530.
54. Reen RK, Jamwal DS, Taneja SC, et al. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intes-tine of rat and guinea pig in vitro by piperine. Biochem Pharmacol. 1993;46(2):229-238.
55. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influ-ence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64(4):353-356.
56. Comblain F, Sanchez C, Lesponne I, Balligand M, Serisier S, Henrotin Y. Curcuminoids extract, hydrolyzed collagen and green tea extract synergically inhibit inflammatory and catabolic mediator’s synthesis by normal bovine and osteoarthritic human chondrocytes in monolayer. PLoS One. 2015;10(3):e0121654.
57. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11(6):R165.
58. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci. 2004;1030:578-586.
59. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol. 2007;73(9):1434-1445.
60. Shakibaei M, Mobasheri A, Buhrmann C. Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro. Genes Nutr. 2011;6(2):171-179.
61. Shakibaei M, Schulze-Tanzil G, John T, Mobasheri A. Curcumin protects human chondrocytes from IL-l1beta-induced inhibition of collagen type II and beta1-integrin expression and activation of caspase-3: an immunomorphological study. Ann Anat. 2005;187(5-6):487-497.
62. Buhrmann C, Mobasheri A, Matis U, Shakibaei M. Curcumin medi-ated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther. 2010;12(4):R127.
63. Clutterbuck AL, Allaway D, Harris P, Mobasheri A. Curcumin reduces prostaglandin E2, matrix metalloproteinase-3 and proteoglycan release in the secretome of interleukin 1beta-treated articular cartilage. F1000Res. 2013;2:147.
64. Yang Q, Wu S, Mao X, Wang W, Tai H. Inhibition effect of curcumin on TNF-alpha and MMP-13 expression induced by advanced glycation end products in chondrocytes. Pharmacology. 2013;91(1-2):77-85.
65. Toegel S, Wu SQ, Piana C, et al. Comparison between chondropro-tective effects of glucosamine, curcumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes. Osteoarthritis Cartilage. 2008;16(10):1205-1212.
66. Lev-Ari S, Strier L, Kazanov D, et al. Curcumin synergistically poten-tiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells. Rheumatology (Oxford). 2006;45(2):171-177.
67. TenBroek EM, Yunker L, Nies MF, Bendele AM. Randomized con-trolled studies on the efficacy of antiarthritic agents in inhibiting carti-lage degeneration and pain associated with progression of osteoarthritis in the rat. Arthritis Res Ther. 2016;18:24.
68. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res. 2009;58(12):899-908.
69. van Delft MA, Huitema LF, Tas SW. The contribution of NF-kappaB signalling to immune regulation and tolerance. Eur J Clin Invest. 2015;45(5):529-539.